STOCK TITAN
  1. Home
  2. Sec-filings
  3. ONC
  4. [Form 4] BeOne Medicines Ltd. Insider Trading Activity

BeOne Medicines options exercise for 30,768 ADS

Baker Bros.-related funds exercised options for 30,768 ADS of BeOne Medicines at $36.83 per ADS, with only indirect pecuniary interests retained.

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) reported that entities associated with Baker Bros. Advisors LP exercised non-qualified share options previously granted to two employees for their past board service and received American Depositary Shares (ADS) on September 14, 2026. A total of 30,768 ADS were reported as received upon exercise of 15,384 share options issued to each of Ranjeev Krishana and Michael Goller at an exercise price of $36.83 per ADS. The funds managed by Baker Bros. Advisors LP have an indirect proportionate pecuniary interest in these ADS, while the employees and Felix J. Baker do not retain direct pecuniary interests in the compensation-related securities. Baker Bros. Advisors LP has voting and dispositive power over the options, RSUs and shares held for the benefit of the funds, and the Baker parties disclaim beneficial ownership except to the extent of their pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN
Role Director | Director | Director | Director | Director | Director
Type Security Shares Price Value
Exercise Non-Qualified Share Options F17, F1, F2, F3, F4, F6, F7, F9, F18 30,768 $0.00 $0.00
Exercise Non-Qualified Share Options F17, F1, F2, F4, F6, F7, F9, F11, F18 30,768 $0.00 $0.00
Exercise American Depositary Shares F14, F1, F2, F3, F4, F5, F6, F7, F8, F9, F18 30,768 $36.83 $1.13M
Exercise American Depositary Shares F14, F1, F2, F4, F5, F6, F7, F8, F9, F11, F18 30,768 $36.83 $1.13M
holding American Depositary Shares F14, F15 -- -- --
holding American Depositary Shares F14, F16 -- -- --
holding Ordinary Shares F12 -- -- --
holding Ordinary Shares F13 -- -- --
holding Ordinary Shares F3, F4, F6, F7, F8, F9, F10 -- -- --
holding Ordinary Shares F4, F6, F7, F8, F9, F10, F11 -- -- --
Holdings After Transaction: Non-Qualified Share Options — 0 contracts (Indirect, See Footnotes); American Depositary Shares — 8,099,179 shares (Indirect, See Footnotes); American Depositary Shares — 20,836 shares (Direct); Ordinary Shares — 2 shares (Direct); Ordinary Shares — 161,546 shares (Indirect, See Footnotes); Ordinary Shares — 161,550 shares (Indirect, See Footnote)
Footnotes (18)
  1. F1. American Depositary Shares ("ADS") of BeOne Medicines Ltd. (the "Issuer") received upon exercise of 15,384 non-qualified share options to purchase ADS or Ordinary Shares ("Share Options") that were issued to each of Ranjeev Krishana and Michael Goller, full-time employees of Baker Bros. Advisors LP (the "Adviser") for their prior service as directors of the Issuer. Ranjeev Krishana and Michael Goller, pursuant to the policies of the Adviser, do not have any right to the pecuniary interest in the Share Options issued for their prior service on the board of directors of the Issuer (the "Board") or the ADS or Ordinary Shares received upon exercise of such Share Options.
  2. F2. Each of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the ADS received upon exercise of the Share Options issued in connection with Ranjeev Krishana and Michael Goller's prior service on the Board less the exercise cost of those Share Options.
  3. F3. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II directly held by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  4. F4. Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his current service on the Board and Ranjeev Krishana and Michael Goller do not have the right to any of the Issuer's securities issued as compensation for their past service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.
  5. F5. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares or ADS received upon vesting of restricted share units (each an "RSU"), Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options, in each case that were received as a result of Felix J. Baker's current or Ranjeev Krishana's and Michael Goller's past service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares or ADS received upon vesting of RSUs, Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options (i.e., no direct pecuniary interest).
  6. F6. The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
  7. F7. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  8. F8. Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares or ADS received as a result of the exercise of Share Options or vesting of RSUs.
  9. F9. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons.
  10. F10. Includes beneficial ownership of 71,279 Ordinary Shares received from vested RSUs previously granted to Michael Goller and 71,266 Ordinary Shares received from vested RSUs previously granted to Ranjeev Krishana in their capacity as prior directors of the Issuer and 18,980 Ordinary Shares underlying 18,980 unvested RSUs granted to Felix J. Baker in his capacity as a director of the Issuer.
  11. F11. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
  12. F12. Ordinary Share held directly by Felix J. Baker.
  13. F13. Ordinary Share held directly by Julian C. Baker.
  14. F14. Each ADS represents 13 Ordinary Shares.
  15. F15. ADS held directly by Felix J. Baker.
  16. F16. ADS held directly by Julian C. Baker.
  17. F17. The Share Options vested in 3 equal annual installments on April 19, 2018, April 19, 2019 and April 19, 2020.
  18. F18. The ADS reported represent a total of 30,768 ADS received upon exercise of 15,384 Share Options issued to each of Ranjeev Krishana and Michael Goller. This amount is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities.
ADS received 30,768 ADS Total ADS received upon exercise of share options granted to two employees
Exercise price per ADS $36.83 per ADS Exercise price for the non-qualified share options into BeOne Medicines ADS
Options per employee 15,384 share options Non-qualified share options issued to each of Ranjeev Krishana and Michael Goller
ADS to Ordinary Share ratio 1 ADS : 13 Ordinary Shares Each American Depositary Share represents 13 Ordinary Shares of BeOne Medicines
Indirect Ordinary Shares holding 161,546 Ordinary Shares Ordinary Shares indirectly held after transactions in one reported line
Indirect Ordinary Shares holding 161,550 Ordinary Shares Ordinary Shares indirectly held after transactions in another reported line
American Depositary Shares financial
"American Depositary Shares ("ADS") of BeOne Medicines Ltd."
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Non-Qualified Share Options financial
"Non-Qualified Share Options to purchase ADS or Ordinary Shares"
restricted share units financial
"Ordinary Shares received upon vesting of restricted share units (each an "RSU")"
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
pecuniary interest financial
"may be deemed to have an indirect pecuniary interest in the securities"
voting and dispositive power financial
"the Adviser has voting and dispositive power over the Share Options, RSUs"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BeOne Medicines (ONC) ADS were received in the reported Form 4 transaction?
The filing states that a total of 30,768 American Depositary Shares (ADS) of BeOne Medicines Ltd. were received upon exercise of 15,384 share options issued to each of Ranjeev Krishana and Michael Goller.

What was the exercise price for the BeOne Medicines (ONC) share options in this Form 4?
The non-qualified share options were exercised at an exercise price of $36.83 per ADS. The Form 4 identifies these as share options to purchase ADS or Ordinary Shares that vested in three equal installments between 2018 and 2020.

Do Felix and Julian Baker have direct ownership of the ONC shares from this option exercise?
The filing explains that Felix J. Baker, Ranjeev Krishana and Michael Goller do not have direct pecuniary interests in the compensation-related securities; the funds have an indirect proportionate pecuniary interest, and the Baker parties disclaim beneficial ownership beyond that.

Who has voting and dispositive power over the BeOne Medicines (ONC) securities involved?
According to the disclosure, Baker Bros. Advisors LP has voting and dispositive power over the share options, RSUs and any Ordinary Shares or ADS received from option exercises or RSU vesting that are held directly by or for the benefit of the funds.

What is the ADS to Ordinary Share ratio for BeOne Medicines (ONC) in this filing?
The Form 4 specifies that each American Depositary Share (ADS) represents 13 Ordinary Shares of BeOne Medicines Ltd., providing the conversion ratio between the ADS and the underlying Ordinary Shares.

Were the reported ONC insider transactions made under a Rule 10b5-1 trading plan?
The document-level checkbox indicates no Rule 10b5-1 trading plan is affirmed for these transactions, and the footnotes do not state that the option exercises or resulting ADS were executed pursuant to a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BAKER BROS. ADVISORS LP
(Last)(First)(Middle)
860 WASHINGTON STREET, 3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American Depositary Shares09/14/2026M30,768A$36.83761,410(14)ISee Footnotes(1)(2)(3)(4)(5)(6)(7)(8)(9)(18)
American Depositary Shares09/14/2026M30,768A$36.838,099,179(14)ISee Footnotes(1)(2)(4)(5)(6)(7)(8)(9)(11)(18)
American Depositary Shares10,418(14)(15)D
American Depositary Shares10,418(14)(16)D
Ordinary Shares1(12)D
Ordinary Shares1(13)D
Ordinary Shares161,546ISee Footnotes(3)(4)(6)(7)(8)(9)(10)
Ordinary Shares161,550ISee Footnote(4)(6)(7)(8)(9)(10)(11)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Share Options$36.8309/14/2026M30,768 (17)12/11/2026American Depositary Shares30,768$00ISee Footnotes(1)(2)(3)(4)(6)(7)(9)(18)
Non-Qualified Share Options$36.8309/14/2026M30,768 (17)12/11/2026American Depositary Shares30,768$00ISee Footnotes(1)(2)(4)(6)(7)(9)(11)(18)
1. Name and Address of Reporting Person*
BAKER BROS. ADVISORS LP
(Last)(First)(Middle)
860 WASHINGTON STREET, 3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
667, L.P.
(Last)(First)(Middle)
860 WASHINGTON STREET, 3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Baker Bros. Advisors (GP) LLC
(Last)(First)(Middle)
860 WASHINGTON STREET, 3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Baker Brothers Life Sciences LP
(Last)(First)(Middle)
860 WASHINGTON STREET, 3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
BAKER FELIX
(Last)(First)(Middle)
860 WASHINGTON STREET, 3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
BAKER JULIAN
(Last)(First)(Middle)
860 WASHINGTON STREET, 3RD FLOOR
(Street)
NEW YORK NEW YORK 10014
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. American Depositary Shares ("ADS") of BeOne Medicines Ltd. (the "Issuer") received upon exercise of 15,384 non-qualified share options to purchase ADS or Ordinary Shares ("Share Options") that were issued to each of Ranjeev Krishana and Michael Goller, full-time employees of Baker Bros. Advisors LP (the "Adviser") for their prior service as directors of the Issuer. Ranjeev Krishana and Michael Goller, pursuant to the policies of the Adviser, do not have any right to the pecuniary interest in the Share Options issued for their prior service on the board of directors of the Issuer (the "Board") or the ADS or Ordinary Shares received upon exercise of such Share Options.
2. Each of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the ADS received upon exercise of the Share Options issued in connection with Ranjeev Krishana and Michael Goller's prior service on the Board less the exercise cost of those Share Options.
3. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II directly held by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
4. Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his current service on the Board and Ranjeev Krishana and Michael Goller do not have the right to any of the Issuer's securities issued as compensation for their past service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.
5. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares or ADS received upon vesting of restricted share units (each an "RSU"), Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options, in each case that were received as a result of Felix J. Baker's current or Ranjeev Krishana's and Michael Goller's past service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares or ADS received upon vesting of RSUs, Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options (i.e., no direct pecuniary interest).
6. The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
7. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
8. Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares or ADS received as a result of the exercise of Share Options or vesting of RSUs.
9. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons.
10. Includes beneficial ownership of 71,279 Ordinary Shares received from vested RSUs previously granted to Michael Goller and 71,266 Ordinary Shares received from vested RSUs previously granted to Ranjeev Krishana in their capacity as prior directors of the Issuer and 18,980 Ordinary Shares underlying 18,980 unvested RSUs granted to Felix J. Baker in his capacity as a director of the Issuer.
11. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
12. Ordinary Share held directly by Felix J. Baker.
13. Ordinary Share held directly by Julian C. Baker.
14. Each ADS represents 13 Ordinary Shares.
15. ADS held directly by Felix J. Baker.
16. ADS held directly by Julian C. Baker.
17. The Share Options vested in 3 equal annual installments on April 19, 2018, April 19, 2019 and April 19, 2020.
18. The ADS reported represent a total of 30,768 ADS received upon exercise of 15,384 Share Options issued to each of Ranjeev Krishana and Michael Goller. This amount is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities.
Remarks:
Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC , the sole general partner of Baker Bros. Advisors LP, is a director of BeOne Medicines Ltd. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer.
By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing09/16/2026
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing09/16/2026
By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing09/16/2026
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., /s/ Name: Scott L. Lessing, Title: President09/16/2026
/s/ Felix J. Baker09/16/2026
/s/ Julian C. Baker09/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on ONC

Trending in the feed

Open the live feed